Dario A. Paggiarino is Chief Medical Officer at EyePoint Pharmaceuticals, Inc. (EYPT). They have made 5 open-market trades across 1 company since 2023, most recently 2024-03-30.
CIK 0001574261
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EYPT | SELL | 2024-01-26 | 2024-01-30 | $25.66 | $2.5M | +11.9% | +5.7% | -31.5% |
| EYPT | SELL | 2024-01-25 | 2024-01-29 | $25.00 | $8K | +10.3% | +4.8% | -33.2% |
| EYPT | SELL | 2024-01-23 | 2024-01-25 | $25.01 | $551K | +16.0% | +6.7% | -33.8% |
| EYPT | SELL | 2024-01-08 | 2024-01-10 | $21.13 | $968K | +25.1% | +44.7% | +8.1% |
| EYPT | SELL | 2023-12-13 | 2023-12-15 | $20.00 | $29K | +22.1% | +18.0% | +12.7% |
| EYPT | SELL · 10b5-1 | 2023-12-04 | 2023-12-06 | $22.00 | $674K | -6.0% | +1.2% | +26.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.